secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001437749-24-009820
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic reports FY2023 net loss of $6.8M; appoints new Chairman and COO
----------------------------------------------------------------------

- Net loss $6.8M ($0.24/share) vs $9.7M loss in 2022; revenue $2.9M flat YoY.
- Cash & investments $7.3M at Dec 31, 2023; raised $6M convertible note in March 2024.
- Positive Phase 1 topline data for DYAI-100 COVID booster: safe and immunogenic.
- Patrick Lucy appointed Chairman, replacing Michael Tarnok (retiring June 2025); Joseph Hazelton named COO.
- Entered multiple funded collaborations including top-ten pharma, Phibro/Abic, Rabian, Massachusetts General Hospital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924009820/0001437749-24-009820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924009820/dyai20231121_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer